Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report

Author:

Dumangin Guillaume1,Brenkman Matthieu1,Pape Elise12,Kolodziej Allan1,Gambier Nicolas12,Vrillon Isabelle3,Charmillon Alexandre4,Scala-Bertola Julien12ORCID

Affiliation:

1. Université de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France

2. Université de Lorraine, CNRS, IMoPA, F-54000 Nancy, France

3. CHRU-Nancy, Department of Pediatric Nephrology, F-54000 Nancy, France

4. CHRU-Nancy, Department of Infectious and Tropical Diseases, F-54000 Nancy, France

Abstract

Abstract Background Temocillin is a carboxypenicillin antibiotic indicated in complicated urinary tract infections due to susceptible ESBL-producing Enterobacteriaceae. While temocillin therapeutic schemes for adult patients with normal or impaired renal function are evidence based, little is known in paediatric populations. Objectives We report herein the management of temocillin treatment in a preterm infant with end-stage renal disease. Patients and methods The patient was a 7-month-old preterm infant born at 35 weeks gestation and treated by temocillin for 10 days for a bacteraemic urinary tract infection due to a susceptible ESBL-producing Enterobacter cloacae complex strain. Temocillin was administered by continuous infusion using a loading dose of 25 mg followed by a maintenance dose of 70 mg daily. Determination of MIC and temocillin plasma and urinary concentration was performed. Results Clinical improvement was observed 24 h after the initiation of temocillin treatment. Temocillin concentrations ranged between 21.6 and 35.5 mg/L in urine between the first and the sixth day of treatment and between 47.0 and 61.8 mg/L in plasma after 6 and 10 days of treatment, respectively. Temocillin concentrations were found to be above the determined MIC of 6 mg/L. From the measured concentrations, we can postulate that 100%fT>MIC was achieved in urine and at least equal to 40% in plasma. Conclusions Temocillin dosing adjustment performed in the present reported case allowed safe and effective treatment. The strategy described herein could be used as a basis for further clinical studies relative to temocillin use in a paediatric population with renal impairment.

Funder

Eumedica Pharmaceuticals

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Reference16 articles.

1. Temocillin revived;Livermore;J Antimicrob Chemother,2009

2. Pharmacokinetics and pharmacodynamics of temocillin;Alexandre;Clin Pharmacokinet,2018

3. Interpretive criteria for temocillin disk diffusion susceptibility testing;Fuchs;Eur J Clin Microbiol,1985

4. Temocillin: is this the right momentum for its global use?;Balakrishnan;Future Microbiol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3